XML 32 R22.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information
 9 Months Ended
Sep. 30, 2025
Segment Information [Abstract]  
Segment Information
15. Segment Information
 
We operate as a single operating segment, Ionis operations, focused on the research, development and commercialization of our RNA-targeted medicines to bring better futures to people with serious diseases. The CODM, our Chief Executive Officer, manages our company, reviews operating results, assesses performance and allocates resources on an aggregate basis using consolidated net income or loss as the key measure of segment profit or loss. As such, results of our operations are reported on a consolidated basis for purposes of management and segment reporting.
 
Ionis operations derives its revenues from commercial and R&D revenue sources. Refer to Note 4, Revenues, for further details on our sources of revenue.
The following table sets forth information on segment profit or loss, including significant segment expenses (in thousands):
 
 Three Months Ended Nine Months Ended
 September 30, September 30,
 2025 2024 2025 2024
Revenue$156,719  $133,814  $740,381  $478,562 
        
Less:       
Cost of sales 2,193   912   7,097   6,815 
Drug discovery 28,412   25,790   85,656   80,652 
Drug development 120,828   132,201   351,463   392,151 
Medical affairs 8,874   5,511   22,342   17,279 
Manufacturing and development chemistry 15,790   14,087   51,616   39,723 
R&D support 23,092   20,052   64,252   59,065 
Selling, general and administrative 86,565   51,933   234,626   153,083 
Other segment items (1) (429)   23,808   75,322   79,342 
Consolidated net loss$(128,606)  $(140,480)  $(151,993)  $(349,548) 
 
(1)  Other segment items include stock-based compensation expense, investment income, interest expense, gain or loss on investments, other income or expense and income tax expense or benefit.